Diamond Therapeutics

Diamond Therapeutics is a biotechnology startup headquartered in Canada, founded in 2018. The company is revolutionizing the treatment of mental health through the development of safe, FDA, EMA, and Health Canada approved therapies for neuropsychiatric conditions. Their focus is on sub-perceptual psilocybin-based medicines, aiming to deliver greater impact than current first-line treatments without perceptual side effects. The recent Venture Round investment at 04 April 2023 saw participation from Noetic Fund and First Avenue Ventures. With a mission to unlock the promise of a new and better class of mental health therapies, Diamond Therapeutics is poised to make a significant impact in the biotechnology and healthcare industries.